A statement released earlier today by TD Securities about Concordia Healthcare Corp (TSE:CXR) bumps down the target price to $7.00
- Updated: September 19, 2016
Just yesterday Concordia Healthcare Corp (TSE:CXR) traded 0.98% lower at $6.76. CXR’s 50-day moving average is $13.53 and its 200-day average is $28.73. The last stock price close is down 75.46% relative to the 200-day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. Trading volume was was down over the average, with 667,595 shares of CXR changing hands under the typical 782,538 shares..
Stating a possible upside of 0.04%, TD Securities lowered the target price of Concordia Healthcare Corp (TSE:CXR) to $7
Previously on Tuesday September 13 2016, RBC Capital Markets released a statement for Concordia Healthcare Corp(TSE:CXR) upped the target price from $0.00 to $32.00 that indicated a possible upside of 2.60%.
See Graph Below:
Also covering Concordia Healthcare Corp’s target price, a total of 10 equity analysts have issued a research note on CXR. The consensus target stock price is $23.13 with 0 rating the company a strong buy, 0 rating the stock a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firms rating the stock as sell.
Concordia Healthcare Corp has a 52 week low of $6.33 and a one-year high of $28.35. Concordia Healthcare Corp’s market capitalization is presently $0.0.
Brief Synopsis On Concordia Healthcare Corp (TSE:CXR)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.